Jindalee Lithium Launches 1-for-19 Share Entitlement Offer at A$0.46

Jindalee Lithium has launched a non-renounceable entitlement offer priced at A$0.46 per share, including attaching options exercisable at A$0.60, aiming to raise capital by early June 2026.

  • Non-renounceable entitlement offer at A$0.46 per share
  • One attaching option per new share exercisable at A$0.60
  • Offer ratio: 1 new share per 19 held
  • Offer opens 18 May and closes 5 June 2026
  • Ineligible shareholders notified and excluded
An image related to Jindalee Lithium Limited
Image © middle. Logo © respective owner.

Entitlement Offer Details and Terms

Jindalee Lithium Limited (ASX:JLL, OTCQX: JNDAF) has formally dispatched the prospectus for its non-renounceable entitlement offer, inviting eligible shareholders to acquire one new fully paid ordinary share for every nineteen shares held as of 13 May 2026. The offer price is set at A$0.46 per new share, accompanied by one attaching option per new share at no additional cost. These options carry an exercise price of A$0.60 and expire on 30 June 2029.

The offer opened on 18 May and is scheduled to close at 3:00pm (Perth time) on 5 June 2026. Eligible shareholders are those registered in Australia or New Zealand and not located in the United States, reflecting compliance with relevant securities laws.

Capital Raising Context and Strategic Use

This entitlement offer forms part of a broader capital raising strategy that includes a recent placement, collectively targeting up to A$11 million to advance Jindalee’s McDermitt Lithium Project and support its US NASDAQ listing ambitions. The offer is designed with no minimum subscription, allowing shareholders to maintain their proportional ownership if they fully participate, or face dilution if they do not.

Shareholders who fully subscribe may also apply for additional shares and options through a top-up offer, with any remaining shortfall potentially offered to the public. This structure aims to maximise capital inflow while managing dilution risks.

Access and Acceptance Process for Shareholders

Jindalee is providing the prospectus and acceptance forms electronically via the Automic Share Registry portal, foregoing physical dispatch. Shareholders can access documents through existing Automic accounts, by registering for a new account, or via single holding access for this offer only. Detailed instructions accompany the prospectus to facilitate smooth participation.

Ineligible shareholders have been notified via letter, ensuring transparency on participation restrictions tied to jurisdictional compliance, particularly the exclusion of US persons. This aligns with the company’s ongoing efforts to comply with securities regulations amid its US market activities.

Regulatory Compliance and Offer Conditions

The offer is lodged with ASIC and ASX, with all capital raising activities subject to Australian and New Zealand securities laws. Jindalee emphasises that this announcement is not financial advice and encourages shareholders to seek professional guidance before subscribing.

Market participants will note the offer’s non-renounceable nature, meaning entitlements cannot be traded or sold, which may influence shareholder decisions. The offer’s success will depend on uptake, with results expected to be announced by 15 June 2026.

This entitlement offer builds on Jindalee’s recent capital initiatives, including a strongly supported placement backed by institutional investors, which collectively aim to fund the McDermitt project development and US listing costs. The company's strategy reflects a push to solidify funding ahead of key project milestones and market expansion efforts A$11M capital raise.

Jindalee’s ongoing US NASDAQ listing progress and federal approvals for McDermitt underpin the rationale for this capital raise, highlighting the company’s dual-market growth ambitions and regulatory navigation NASDAQ listing and US permitting.

Bottom Line?

The entitlement offer provides shareholders a chance to maintain stake ahead of McDermitt development milestones, but uptake and shortfall results will be critical to watch.

Questions in the middle?

  • Will shareholder uptake meet the offer’s capital raising targets?
  • How will dilution impact shareholder value if entitlements are not fully subscribed?
  • Could changes to the closing date or offer terms affect market reception?